NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Aptevo Therapeutics Inc (NASDAQ: APVO)

 
APVO Technical Analysis
3
As on 5th Aug 2025 APVO SHARE Price closed @ 2.45 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.57 & Buy for SHORT-TERM with Stoploss of 2.31 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

APVOSHARE Price

Open 2.55 Change Price %
High 2.60 1 Day -0.14 -5.41
Low 2.36 1 Week -0.61 -19.93
Close 2.45 1 Month -0.80 -24.62
Volume 121856 1 Year 2.30 1533.33
52 Week High 10.01 | 52 Week Low 0.13
 
NASDAQ USA Most Active Stocks
AMRS 0.14 100.00%
ADAP 0.10 25.00%
OPEN 2.52 2.44%
NVDA 178.26 -0.97%
OTRK 0.39 39.29%
LMDX 0.02 0.00%
AKTS 0.04 0.00%
INTC 20.19 3.54%
STTK 0.99 33.78%
NCNA 0.04 -20.00%
 
NASDAQ USA Top Gainers Stocks
MRIN 3450.00 383233.34%
MRIN 3450.00 383233.34%
KTRA 6.30 2763.64%
IDRA 8.64 1909.30%
ACXP 5.09 1655.17%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
ZVZZT 49.98 312.38%
NBSTU 12.99 220.74%
NDRAW 0.03 200.00%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
ORGS 0.02 -81.82%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
AXAS 0.03 -70.00%
BPTH 0.21 -66.67%
AXDX 0.03 -66.67%
TFFP 0.06 -62.50%
HEPA 0.05 -58.33%
 
 
APVO
Daily Charts
APVO
Intraday Charts
Whats New @
Bazaartrend
APVO
Free Analysis
 
APVO Important Levels Intraday
RESISTANCE2.91
RESISTANCE2.76
RESISTANCE2.67
RESISTANCE2.58
SUPPORT2.32
SUPPORT2.23
SUPPORT2.14
SUPPORT1.99
 
APVO Forecast August 2025
4th UP Forecast23.03
3rd UP Forecast16.43
2nd UP Forecast12.35
1st UP Forecast8.27
1st DOWN Forecast-3.37
2nd DOWN Forecast-7.45
3rd DOWN Forecast-11.53
4th DOWN Forecast-18.13
 
APVO Weekly Forecast
4th UP Forecast2.57
3rd UP Forecast2.53
2nd UP Forecast2.51
1st UP Forecast2.48
1st DOWN Forecast2.42
2nd DOWN Forecast2.39
3rd DOWN Forecast2.37
4th DOWN Forecast2.33
 
APVO Forecast2025
4th UP Forecast30.93
3rd UP Forecast21.8
2nd UP Forecast16.15
1st UP Forecast10.51
1st DOWN Forecast-5.61
2nd DOWN Forecast-11.25
3rd DOWN Forecast-16.9
4th DOWN Forecast-26.03
 
 
APVO Other Details
Segment EQ
Market Capital 73507736.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
APVO Address
APVO
 
APVO Latest News
 
Your Comments and Response on Aptevo Therapeutics Inc
 
APVO Business Profile
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Address: 2401 4th Avenue, Seattle, WA, United States, 98121
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service